Industry's Italian Drug Price Challenge Fails

20 February 1995

Italy's pharmaceutical manufacturers were last week preparing to implement the further 2.5% drug price reduction imposed by the government, following the failure of an attempt by a group of companies to prevent the measure from being introduced.

This latest price cut affects only companies reporting an increase in turnover of 10% or more in the first half of 1994. Around 62 companies are involved, and the prices of about 1,400 products overall are to be cut, according to the pharmacists' association, Federfarma.

The provision, which was contained in a decision announced in early January by the interministry policy-making committee, Cipe (Marketletter January 16), had been challenged by a group of pharmaceutical manufacturers, which launched an appeal in the regional administrative court in Latium. Last week however, the court dismissed the appeal brought by the group, which included multinationals such as Glaxo, Schering-Plough, Parke-Davis and Bristol-Myers Squibb.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight